MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Ionis Pharmaceuticals Inc

Deschisă

SectorSănătate

29.67 1.12

Rezumat

Modificarea prețului

24h

Curent

Minim

28.69

Maxim

29.84

Indicatori cheie

By Trading Economics

Venit

36M

-104M

Vânzări

93M

227M

P/E

Medie Sector

539.57

57.333

EPS

-0.43

Marjă de profit

-46.055

Angajați

1,069

EBITDA

44M

-81M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+87.59% upside

Dividende

By Dow Jones

Următoarele câștiguri

30 apr. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-162M

4.5B

Deschiderea anterioară

28.55

Închiderea anterioară

29.67

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

Ionis Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 sept. 2024, 17:01 UTC

Top știri

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 sept. 2024, 11:00 UTC

Top știri

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Comparație

Modificare preț

Ionis Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

87.59% sus

Prognoză pe 12 luni

Medie 55.47 USD  87.59%

Maxim 78 USD

Minim 38 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIonis Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

20 ratings

12

Cumpărare

8

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

29.04 / 30.12Suport & Rezistență

Termen scurt

Very Strong Bullish Evidence

Termen mediu

Neutral Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.